Latest Conference Articles

September 15th 2017, 12:08am

Lynn Sage Breast Cancer Symposium

Judith Paice, PhD, RN, director of the Cancer Pain Program, Division of Hematology-Oncology, and research professor of Medicine, Northwestern University, discusses the pain management for patients with breast cancer.

September 14th 2017, 12:20pm

ESMO Congress

Although anti-PD-1/PD-L1 immunotherapy has greatly improved the treatment of patients with non–small cell lung cancer and is generally well-tolerated, the therapy backfires in a newly defined subset of patients who experience accelerated tumor growth indicative of hyperprogressive disease.

September 13th 2017, 10:25pm

ESMO Congress

Nearly half of patients with resectable stage IIIB/C BRAF V600-mutant melanoma achieved pathologic complete response with neoadjuvant combination therapy consisting of dabrafenib (Tafinlar) and trametinib (Mekinist).

September 13th 2017, 7:50pm

ESMO Congress

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the significance of the PACIFIC trial in patients with non

September 13th 2017, 7:27pm

ESMO Congress

Pembrolizumab (Keytruda) reduced the risk of death compared with standard of care therapy in patients with relapsed/metastatic head and neck squamous cell carcinoma, but the difference fell just shy of statistical significance.

September 13th 2017, 7:18pm

ESMO Congress

Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses both the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).

September 13th 2017, 5:48pm

ESMO Congress

Adjuvant therapy with vemurafenib for high-risk melanoma led to mixed results, as patients with stage IIIC or later did not benefit, but those with earlier stage disease did.

September 13th 2017, 12:39am

ESMO Congress

Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

September 13th 2017, 12:06am

ESMO Congress

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the phase III results of the FLAURA trial, which explored osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

September 12th 2017, 11:16pm

ESMO Congress

The combination of bevacizumab plus niraparib demonstrated clinical activity in women with relapsed, platinum-sensitive epithelial ovarian cancer and had a manageable toxicity profile.

September 12th 2017, 10:16pm

ESMO Congress

Although second-line treatment with combined pazopanib and gemcitabine demonstrated disease control in the majority of patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas, the phase II UNICANCER SARCOME 11 study did not meet statistical endpoints and is considered a negative trial.

September 12th 2017, 8:35pm

ESMO Congress

Treating primary tumors by administering targeted therapy with sunitinib (Sutent) prior to cytoreductive nephrectomy did not improve the progression-free rate at 28 weeks over a sequence of immediate CN followed by sunitinib in patients with synchronous metastatic renal cell carcinoma.

September 12th 2017, 4:53pm

ESMO Congress

Nivolumab (Opdivo) may represent a new standard option for adjuvant therapy for patients with resected stage IIIB/C and IV melanoma, whether or not they have a BRAF mutation. In a comparison with current standard high-dose ipilimumab (Yervoy), nivolumab demonstrated a significant improvement in relapse-free survival.

September 11th 2017, 11:46pm

ESMO Congress

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was superior to sunitinib (Sutent) monotherapy as first-line treatment of advanced or metastatic renal cell carcinoma.

September 11th 2017, 11:13pm

ESMO Congress

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase III results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

September 11th 2017, 9:43pm

ESMO Congress

Ramucirumab (Cyramza) plus docetaxel improved progression-free survival over docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.

September 11th 2017, 9:29pm

ESMO Congress

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the CheckMate-238 trial for patients with melanoma.

September 11th 2017, 9:29pm

ESMO Congress

Solange Peters, MD, PhD, head of the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne in Switzerland, discusses the FLAURA trial for patients with EGFR-mutated non

September 11th 2017, 8:58pm

ESMO Congress

Patients with untreated advanced renal cell carcinoma lived significantly longer without disease progression when they received the multikinase inhibitor cabozantinib (Cabometyx) as initial therapy versus sunitinib (Sutent).

September 11th 2017, 6:39pm

ESMO Congress

Lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) demonstrated promising antitumor activity in patients with metastatic clear cell renal cell carcinoma.